1 July 2025

A step forward for CF treatment access in Aotearoa.

Today, Pharmac released their provisional recommendation from the May PTAC meeting. CFNZ is pleased to see that Alyftrek has received a high priority which is good news for those who are unable to access or benefit from Trikafta. 

CFNZ is committed to working closely with Pharmac and Vertex to progress the application alongside access to Trikafta for 2-5 year olds, and expanded access to Kalydeco.

We are encouraged by Pharmac’s increased transparency and continue to ask that decisions are made without delay, so that people with CF across Aotearoa can access a CFTR modulator that works for them.

You can read the released PTAC provisional recommendation here>

A full version of the meeting minutes will be published at a later date, and we’ll share updates as soon as they’re available.